Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myofilament-based physiological regulatory compensation preserves diastolic function in failing hearts with severe Ca2+ handling deficits
Frazer I. Heinis, Brian R. Thompson, Rishi Gulati, Matthew Wheelwright, Joseph M. Metzger
Frazer I. Heinis, Brian R. Thompson, Rishi Gulati, Matthew Wheelwright, Joseph M. Metzger
View: Text | PDF
Research Article Cardiology

Myofilament-based physiological regulatory compensation preserves diastolic function in failing hearts with severe Ca2+ handling deficits

  • Text
  • PDF
Abstract

Severe dysfunction in cardiac muscle intracellular Ca2+ handling is a common pathway underlying heart failure. Here we used an inducible genetic model of severe Ca2+ cycling dysfunction by the targeted temporal gene ablation of the cardiac Ca2+ ATPase, SERCA2, in otherwise normal adult mice. In this model, in vivo heart performance was minimally affected initially, even though Serca2a protein was markedly reduced. The mechanism underlying the sustained in vivo heart performance in the weeks prior to complete heart pump failure and death is not clear and is important to understand. Studies were primarily focused on understanding how in vivo diastolic function could be relatively normal under conditions of marked Serca2a deficiency. Interestingly, data show increased cardiac troponin I (cTnI) serine 23/24 phosphorylation content in hearts upon Serca2a ablation in vivo. We report that hearts isolated from the Serca2-deficient mice retained near normal heart pump functional responses to β-adrenergic stimulation. Unexpectedly, using genetic complementation models, in concert with inducible Serca2 ablation, data show that Serca2a-deficient hearts that also lacked the central β-adrenergic signaling–dependent Serca2a negative regulator, phospholamban (PLN), had severe diastolic dysfunction that could still be corrected by β-adrenergic stimulation. Notably, integrating a serines 23/24–to–alanine PKA-refractory sarcomere incorporated cTnI molecular switch complex in mice deficient in Serca2 showed blunting of β-adrenergic stimulation–mediated enhanced diastolic heart performance. Taken together, these data provide evidence of a compensatory regulatory role of the myofilaments as a critical physiological bridging mechanism to aid in preserving heart diastolic performance in failing hearts with severe Ca2+ handling deficits.

Authors

Frazer I. Heinis, Brian R. Thompson, Rishi Gulati, Matthew Wheelwright, Joseph M. Metzger

×

Figure 5

Effects of myofilament incorporation of cTnI(Ala2) on LV performance in Serca2 gene–ablated hearts.

Options: View larger image (or click on image) Download as PowerPoint
Effects of myofilament incorporation of cTnI(Ala2) on LV performance in ...
(A) Breeding scheme. Serca2fl/fl × cTnIAla2 breeding scheme. Serca2fl/fl;Tg:αMHC-MerCreMer mice were bred with mice expressing a PKA-insensitive mutant of cardiac troponin I, cTnIAla2, in which the PKA target serines 23/24 have been mutated to alanine. To ensure complete expression of the PKA-insensitive transgene, this line is maintained as cTnI–/–;Tg:αMHC-cTnIAla2. Heterozygous siblings were bred to homozygosity to create the mouse line Serca2fl/fl; cTnI–/–;Tg:αMHC-MerCreMer;Tg:αMHC-cTnIAla2, in which PKA phosphorylation of cTnI cannot contribute to the lusitropic response upon β-adrenergic stimulation. (B) Representative original LV pressure recordings in Serca2-FL and -KO hearts with complete cTnI(Ala2) incorporation into the myofilaments and studied in the presence or absence of acute β-adrenergic stimulation. (C) LV end-diastolic pressures of FL and SERCA2-KO hearts expressing cTnIAla2. Isoproterenol perfusion reduces LVEDP in both groups, but SERCA2-KO hearts are unable to completely relax at high-pacing frequencies. FL (n = 9) and SERCA2-KO (n = 5) hearts all expressed PKA-insensitive cTnIAla2, during pacing challenge. (D) T50Relax times during pacing challenge of FL and KO hearts expressing cTnIAla2. Isoproterenol perfusion decreases T50Relax in both FL and KO groups. KO hearts perfused with isoproterenol remain significantly slower than isoproterenol-perfused FL hearts. Two-way ANOVA with Bonferroni post hoc tests: FL + ISO versus KO + ISO tests are P < 0.01 or lower for all pacing frequencies except 12 Hz (P > 0.05). (E) LVEDP as a measure of relaxation is reduced with ISO. *P < 0.05. (F) Western blots of SERCA2, p-cTnI, total cTnI, p-PLN, and total PLN. –P, PLN-KO control; M, marker. Quantification of p-PLN to total PLN content graphically represented. *P = 0.0166, n = 5 per group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts